Shares of Histogenics Corp. (NASDAQ:HSGX) saw strong trading volume on Tuesday . 491,560 shares were traded during mid-day trading, an increase of 554% from the previous session’s volume of 75,111 shares.The stock last traded at $3.55 and had previously closed at $2.82.

Several research analysts have issued reports on the company. BTIG Research raised Histogenics Corp. from a “neutral” rating to a “buy” rating and set a $3.50 price target on the stock in a report on Thursday, August 11th. Canaccord Genuity reaffirmed a “buy” rating on shares of Histogenics Corp. in a report on Thursday, May 12th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $9.75.

The stock’s 50 day moving average is $1.93 and its 200 day moving average is $2.18. The stock’s market cap is $48.98 million.

Histogenics Corp. (NASDAQ:HSGX) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($0.61) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by $0.01. During the same period in the prior year, the business earned ($0.58) EPS. On average, analysts anticipate that Histogenics Corp. will post ($2.09) earnings per share for the current year.

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.